Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Upon determination of eligibility, patients will receive:

• Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab

Patients that are not considered candidates for anthracycline therapy will not receive mitoxantrone. Patients with objective response (partial or complete response) or stable disease will receive Rituximab maintenance therapy.

Inclusion criteria

To be included in this study, you must meet the following criteria:

• Histologically documented large B-cell, CD20-positive non-Hodgkin's lymphoma
• No previous treatment
• Clinical stage II, III, or IV by the Ann Arbor Staging Criteria
• Age > 70 years
• ECOG performance status 0, 1, or 2
• Adequate bone marrow, liver and kidney function
• Must give written informed consent prior to entering this trial

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

• Age < 18 years
• Central nervous system involvement with lymphoma
• Coexistent active malignancies treated within five years
• Active infection precluding the use of combination chemotherapy
• HIV infection
• Pregnant or lactating

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.